Table 3 Association between SIRT1 rs3758391 and clinical characteristics of DLBCL patients
From: SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population
Variables | No. | Genotype | p | |
|---|---|---|---|---|
(n = 206) n (%) | CC + CT n (%) | TT n (%) | ||
Gender | ||||
Male | 97 (47.09) | 52 (25.24) | 45 (21.84) | 0.268 |
Female | 109 (52.91) | 50 (24.27) | 59 (28.64) | |
Age | ||||
≤ 60 | 145 (70.39) | 76 (36.89) | 69 (33.50) | 0.199 |
> 60 | 61 (29.61) | 26 (12.62) | 35 (16.99) | |
B symptom | ||||
+ | 64 (31.07) | 28 (13.59) | 36 (17.48) | 0.267 |
− | 142 (68.93) | 74 (35.92) | 68 (33.01) | |
Subtype | ||||
GCB | 63 (30.58) | 32 (15.53) | 31 (15.05) | 0.807 |
nGCB | 143 (69.42) | 70 (33.98) | 73 (35.44) | |
Ann-arbor stage | ||||
I–II | 132 (64.08) | 61 (29.61) | 71 (34.47) | 0.205 |
III–IV | 74 (35.92) | 41 (19.90) | 33 (16.02) | |
IPI score | ||||
0–1 | 106 (51.46) | 58 (28.16) | 48 (23.30) | 0.124 |
2–5 | 100 (48.54) | 44 (21.36) | 56 (27.18) | |
ECOG | ||||
0–1 | 193 (93.69) | 97 (47.09) | 96 (46.60) | 0.410 |
2–5 | 13 (6.31) | 5 (2.43) | 8 (3.88) | |
Extra nodal sites | ||||
+ | 126 (61.17) | 67 (32.52) | 59 (28.64) | 0.187 |
− | 80 (38.83) | 35 (16.99) | 45 (21.84) | |
Bulky tumor (> 10 cm) | ||||
+ | 48 (23.30) | 26 (12.62) | 22 (10.68) | 0.462 |
− | 158 (76.70) | 76 (36.89) | 82 (39.81) | |
Bone marrow involvement | ||||
+ | 11 (5.34) | 5 (2.43) | 6 (2.91) | 0.782 |
− | 195 (94.66) | 97 (47.09) | 98 (47.57) | |
Elevated LDH | ||||
+ | 85 (41.26) | 46 (22.33) | 39 (18.93) | 0.268 |
− | 121 (58.73) | 56 (27.18) | 65 (31.55) | |
Elevated β2-MG | ||||
+ | 61 (29.61) | 28 (13.59) | 33 (16.02) | 0.501 |
− | 145 (70.39) | 74 (35.92) | 71 (34.47) | |
HBV infection | ||||
+ | 45 (21.84) | 23 (11.17) | 22 (10.68) | 0.809 |
− | 161 (78.16) | 79 (38.35) | 82 (39.81) | |
KI-67 | ||||
≤ 75% | 96 (46.60) | 42 (20.39) | 54 (26.21) | 0.122 |
> 75% | 110 (53.40) | 60 (29.13) | 50 (24.27) | |